Oil prices dip on fears of slowing demand, oversupply
James George Chopas, VP and Chief Accounting Officer at Apellis Pharmaceuticals Inc (NASDAQ:APLS), sold 548 shares of common stock on September 2, 2025, at a price of $28.077, for a total value of $15386. According to InvestingPro analysis, Apellis currently shows a GOOD financial health score, with analysts maintaining a bullish stance on the stock. The company’s shares have gained over 17% in the past six months, despite broader market volatility.
Following the transaction, Chopas directly owns 53657 shares of Apellis Pharmaceuticals. The sale was executed to cover tax withholding on Restricted Stock Units released on August 29, 2025. InvestingPro data reveals the company’s strong revenue growth of 20% and indicates the stock is currently trading near its Fair Value. Discover 8 more exclusive InvestingPro Tips and comprehensive analysis in the Pro Research Report.
In other recent news, Apellis Pharmaceuticals Inc. announced its Q2 2025 earnings, exceeding expectations with a smaller-than-expected loss in earnings per share (EPS). The company reported an EPS of -$0.33, which was better than the anticipated -$0.48. However, revenue did not meet projections, coming in at $178 million compared to the forecasted $186.76 million. Despite the revenue shortfall, the positive EPS surprise has contributed to increased investor confidence. The company’s strategic advancements in product development also played a role in bolstering investor sentiment. These developments come amid a significant pre-market stock surge, although the article does not provide further details on the stock movement. Analysts and investors are closely watching Apellis Pharmaceuticals for future updates on its financial performance and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.